Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Taneasy vs Actein in COPD
NCT06688292Phase 4Completed
- Sponsor
- Bun Yao Biotechnology Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of azelastine + fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Bun Yao Biotechnology Co., Ltd. Primary endpoints: COPD Assessment Test at 14 days and Safety and Efficacy Evaluation at 14 days. Started Sep 2024; status: completed.
02
Drugs
azelastine + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06688292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688292.